AHA at a glance
Get ready for AHA 2025 with LucidQuest’s concise preview. We spotlight must-see sessions and emerging themes in cardiovascular science and AI.
📅 Build your schedule around the topics that interest you. 📥 Download the AHA 2025_Preview_by_LucidQuest
Dive deeper
Key Topics From Notable Presentations
Atrial Fibrillation & Arrhythmias
- PFA beat thermal, delivering 12-month arrhythmia-free survival.
- Elderly ≥80 showed increased stroke, heart failure, and mortality.
- Academic centers had fewer redo ablations and AKI.
Lipid Management & Atherosclerosis
- Obicetrapib cut LDL-C, ApoB, non-HDL-C, and raised HDL-C.
- Recaticimab, a long-acting anti-PCSK9, reduced LDL-C.
- ANGPTL3 inhibition, including evinacumab, lowered LDL-C and triglycerides.
Valvular & Structural Heart Disease
- Post-SAVR rehabilitation reduced mortality and MACE; participation <50%.
- Ataciguat slowed CAVS progression.
- TAVR embolic protection did not reduce strokes.
Coronary Artery Disease & Ischemic Heart Disease
- Vericiguat for ACS with LVEF <45% reduced events and improved QoL.
- ICI rechallenge was viable.
- P2Y12 monotherapy beat aspirin post-PCI.
Vascular & Peripheral Artery Disease
- Smoking-related PAD DALYs declined in high-SDI, slowed in the U.S.
- Ticagrelor + aspirin gave no benefit.
- APOs increased PAD risk.
Heart Failure & Cardiomyopathies
- Aficamten improved PROs and reduced oHCM severity.
- Structured exercise improved capacity and remodeling without arrhythmias.
- Mavacamten with standard therapy reduced hospitalizations and instability.
Hypertension & Renal/Cardiorenal Syndrome
- Aldosterone synthase inhibitors, including lorundrostat, reduced BP with tolerability.
- GMRx2 low-dose triple pill maintained 1-year control.
- Amiloride matched spironolactone efficacy.
Metabolic, Obesity & Diabetes (Cardiometabolic Studies)
- VK2735 (GIP/GLP-1) drove weight loss and improvements.
- GLP-1 RAs reduced MACE.
- Semaglutide 2.4 mg (SELECT) reduced MACE and HF.
Prevention, Lifestyle & Public Health
- Psyllium improved glycemia in T2D.
- Produce prescriptions lowered BP.
- Medically tailored meals were cost-efficient.
- Gamification increased activity.
Stroke & Cerebrovascular Disease
- OAC monotherapy beat OAC + SAPT in bleeding and MI.
- Thrombolysis worsened stroke outcomes.
- EVT offered no benefit over BMT for DMVO.
Artificial Intelligence & Machine Learning at AHA 2025
AI-Enhanced ECG for Structural Heart Disease Detection
- Wearable-integrated AI validated on 266,054 ECGs with 86% sensitivity and 87% specificity for SHD screening.
AI for Diastolic Dysfunction in Cardiomyopathies
- AI-enabled ECG predicted diastolic dysfunction with 94% sensitivity in hypertrophic and amyloid cardiomyopathies.
AI in Hypertrophic Cardiomyopathy Screening
- VIZ-HCM identified undiagnosed cases from EKGs, shortening timelines and improving SCD risk stratification.
AI-Based AF Ablation Guidance
- coMAP predicted ablation success 82.4% vs 48.2%, outperforming conventional selection.
Real-Time AI Guidance for AF Ablation
- coPilot guided catheters to termination sites with 85.7% accuracy, reducing ablation time.
📅 Build your schedule around the topics that interest you.
📥 Download the AHA 2025_Preview_by_LucidQuest
Contact us for end-to-end conference coverage.